Biocon Allots 11.26 Cr Shares Via QIP, Raises ₹4,150 Crore
Biocon Limited has allotted 11,26,64,585 equity shares at ₹368.35 per share via Qualified Institutions Placement (QIP). The issue raised approximately ₹4,150 crore. The company's paid-up equity share capital has increased following this allotment. The trading window will reopen on January 17, 2026.
The QIP raised ₹4,150 crore and increased the company's equity share capital, which can have a substantial impact on its financial structure, growth prospects, and valuation.
The company successfully raised a significant amount of capital through a Qualified Institutions Placement, which is generally viewed positively as it strengthens the company's financial position and provides funds for growth.
Biocon Limited announced the successful allotment of 11,26,64,585 equity shares of face value ₹5 each, as part of its Qualified Institutions Placement (QIP) Issue. The issue price was fixed at ₹368.35 per equity share, including a premium of ₹363.35 per share.
This placement aggregates to ₹41,500 million (₹4,150 crore). The QIP opened on January 12, 2026, and closed on January 14, 2026. The Fund Raising Committee of the company approved the allotment in its meeting held on January 14, 2026.
Following the allotment, Biocon's paid-up equity share capital has increased from ₹754.12 crore (1,50,82,43,188 equity shares) to ₹810.45 crore (1,62,09,07,773 equity shares).
The company also informed that the trading window for dealing in its securities, which was closed for the purpose of the QIP, will reopen on January 17, 2026.
Annexure 1 lists the major allottees who received more than 5% of the Equity Shares offered in the Issue, with SBI CONTRA FUND and ICICI PRUDENTIAL VALUE FUND being significant subscribers.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.